



# Induction of Neutralizing Immunity against SARS-CoV-2 Omicron Variant by COVID-19 Vaccine Boosters

Cheepsattayakorn A<sup>1,2\*</sup> Cheepsattayakorn R<sup>3</sup> and Siriwanarangsun P<sup>1</sup>

<sup>1</sup>Faculty of Medicine, Western University, Pathumtani Province, Thailand

<sup>2</sup>10th Zonal Tuberculosis and Chest Disease Center, Thailand

<sup>3</sup>Department of Pathology, Faculty of Medicine, Chiang Mai University, Thailand

**\*Corresponding author:** Attapon Cheepsattayakorn, 10th Zonal Tuberculosis and Chest Disease Center, 143 Sridornchai Road Changklan Muang Chiang Mai 50100, Thailand, Tel: 66 53 140767; 66 53 276364; Fax: 66 53 140773; 66 53 273590; Email: Attapon1958@gmail.com

## Editorial

Volume 6 Issue 2

Received Date: February 21, 2022

Published Date: March 17, 2022

DOI: 10.23880/mjccs-16000311

## Editorial

The Omicron variant (BA.1/B.1.1.529) is characterized by mutation of an unusually high number, with 26 to 32 changes (up to 36 mutations) in the spike (S) glycoprotein, the key epitopes (target) of neutralizing antibodies [1-3]. A recent study revealed that the Omicron variant is more likely to cause reinfection than previous SARS-CoV-2 variants, indicating some immune-escape levels [4]. Recently, neutralization potency of sera mRNA-1273, BNT162b2, and Ad26.COVS vaccine recipients against wild-type, Delta, and Omicron SARS-CoV-2 pseudoviruses was studied and demonstrated potent neutralization of Omicron variant and 4-6-fold lower than the wild type among mRNA vaccinated individuals, indicating enhanced cross-reactivity of neutralizing antibody responses [2,4]. Polyclonal sera from persons vaccinated with two doses of the BNT162b2 COVID-19 vaccine and from convalescent persons showed a near-complete lack of neutralizing activity against Omicron variant, as well as different monoclonal-antibodies resistance in clinical application [2,3].

## Conclusion

In conclusion, the significance of additional mRNA-

vaccine doses, at least two doses to promote neutralizing antibody (humoral immune) responses against divergent SARS-CoV-2 variants, particularly the Omicron variant.

## References

1. Network for Genomic Surveillance in South Africa (NGS-SA). SARS-CoV-2 sequencing update. November 26, 2021.
2. Garcia-Beltran WF, St. Denis KJ, Hoelzemer A, Lam EC, Nitido AD, et al. (2022) mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. *Cell* 185(3): 457-466.
3. Gruell H, Vanshylla K, Tober-Lau P, Hillus D, Schommers P, et al. (2022) mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant. *Nature Medicine* pp: 1-4.
4. Riepler L, Bante D, von Laer D, Kimpel J (2022) SARS-CoV-2 Omicron variant neutralization in serum from vaccinated and convalescent persons. *N Engl J Med* 386: 698-700.

